Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data

Benzinga05:19

Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593337453?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/22/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-12-23 05:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593337453","market":"hk","top_or_hot":-1,"title":"Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data","media":"Benzinga","content":"<div>\n<p>Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data","article_id":"2593337453","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/22/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49549831/nektar-therapeutics-nktr-stock-slides-despite-analyst-optimism-on-alopecia-data","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593337453","pubTimestamp":1766438340,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Nektar Therapeutics  stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what investors need to know.What To Know: While the study for severe alopecia areata demonstrated a proof-of-concept, it narrowly missed its primary endpoint for the full patient cohort.The investigational biologic failed to achieve statistical significance in the intent-to-treat analysis, showing a mean SALT score reduction of 28.2% and 30.3% in the treatment arms versus 11.2% for placebo .However, Nektar reported that when excluding four patients with major eligibility violations, both dosage arms achieved statistical significance . The company highlighted that rezpegaldesleukin more than doubled the treatment effect of placebo and plans to advance the drug into Phase 3 development in 2026.Despite the sell-off, Wall Street analysts responded with bullish revisions following the data release. BTIG maintaine","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4007":"制药"},"translate_title":"尽管分析师对脱发数据持乐观态度，Nektar Therapeutics(NKTR)股价仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what investors need to know.\nWhat To Know: While the study for severe alopecia areata demonstrated a proof-of-concept, it narrowly missed its primary endpoint for the full patient cohort.\nThe investigational biologic failed to achieve statistical significance in the intent-to-treat analysis, showing a mean SALT score reduction of 28.2% and 30.3% in the treatment arms versus 11.2% for placebo (p=0.186 and p=0.121). \nHowever, Nektar reported that when excluding four patients with major eligibility violations, both dosage arms achieved statistical significance (p<0.05). The company highlighted that rezpegaldesleukin more than doubled the treatment effect of placebo and plans to advance the drug into Phase 3 development in 2026.\nDespite the sell-off, Wall Street analysts responded with bullish revisions following the data release. BTIG maintained a Buy rating and raised its price target to $118 from $100, while H.C. Wainwright & Co. hiked its target to $135 from $120, implying an upside of over 200%. \nAnalysts appear encouraged by the clean safety profile and the drug's potential as a first-in-class Treg mechanism, viewing the adjusted data as a validation of efficacy despite the headline miss.\nBenzinga Edge Rankings: According to Benzinga Edge rankings, NKTR currently maintains a high Momentum score of 98.98, although its price trend indicates caution with a positive outlook only for the long term while short and medium trends are currently marked as unfavorable.\nNKTR Price Action: Nektar Therapeutics shares closed Monday lower by 7.17% at $43.48, according to Benzinga Pro data.\nThe current price is notably 24.2% below the recent average price, indicating that the stock has faced considerable selling pressure. \nDespite this downturn, it remains 38% above its longer-term average, suggesting a potential area of support that could stabilize the price if selling continues.\nRead Also:      • Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593337453","isCrawlerRequest":true}